在自体主导性阿尔茨海默氏症进展过程中皮层不对称
Agnès Pérez-Millan1,2,3, Neus Falgàs1,3, Beatriz Bosch1,3
1Alzheimer's Disease and Other Cognitive Disorders Group, Service of Neurology, Hospital Clínic de Barcelona. Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona 08036, Spain.
Brain communications
|January 12, 2026
概括
通过皮质不对称指数测量的大脑不对称性,可以帮助检测自体主导性阿尔茨海默病突变的携带者早期阿尔茨海默病进展. 这种大脑不对称性标志物对监测与疾病相关的变化充满希望.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 遗传学 是一个遗传学.
背景情况:
- 自体主导性阿尔茨海默病 (ADAD) 呈现出从无症状到症状阶段的独特连续性.
- 了解大脑变化,特别是不对称性,对于早期发现和监测ADAD至关重要.
- 用皮质不对称指数 (CAI) 量化的皮质厚度不对称性在ADAD频谱中尚未得到广泛研究.
研究的目的:
- 研究健康对照,无症状ADAD突变携带者和症状ADAD突变携带者之间的CAI差异.
- 探索CAI与临床状态,遗传因素 (APOE ε4) 和ADAD生物标志物 (神经丝光) 的关联.
- 为了检查与疾病进展有关的CAI的纵向变化.
主要方法:
- 从两个队列中使用T1加权的MRI扫描:巴塞罗那诊所 (n=60) 和主导性遗传阿尔茨海默症网络 (DIAN) 观察研究 (n=564).
- 使用Freesurfer和开源管道计算CAI.
- 进行了横截面和纵向分析,包括与神经丝光 (NfL) 水平和微型心理状态检查 (MMSE) 得分的相关性,并根据相关的共变量进行调整.
主要成果:
- CAI将突变载体 (无症状和有症状) 与巴塞罗那诊所队列中的对照区分开来,以及症状载体与DIAN队列中的对照区分开来.
- 较高的CAI与增加的NfL相关,接近症状发作,并在两个队列中较低的MMSE得分.
- APOE3/3基因型与更大的不对称性有关,并且在症状ADAD突变载体中,CAI在纵向上升.
结论:
- 皮层不对称指数作为早期ADAD检测和监测的潜在成像生物标志物.
- 大脑不对称性变化反映了与ADAD进展相关的神经解剖学变化.
- CAI对跟踪与疾病相关的变化有影响,并可能有助于临床试验监测.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801


